The United Laboratories International Holdings Limited (HKG:3933) Looks Inexpensive But Perhaps Not Attractive Enough
Feb 09
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Healthcare Sector Analysis
UpdatedFeb 14, 2026
DataAggregated Company Financials
Companies222
- 7D3.5%
- 3M-6.8%
- 1Y62.0%
- YTD6.7%
Shanghai Bao Pharmaceuticals is up 50%, leading the way for the Healthcare industry, which has gained 3.5%. During this same period, the 160 Health International underperformed, falling 32%. This takes the industry's 12 month performance to a gain of 62%. Looking forward, earnings are forecast to grow by 30% annually.
Sector Valuation and Performance
Has the Hong Kong Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 14 Feb 2026 | HK$2.6t | HK$1.4t | HK$33.8b | 16.9x | 78.1x | 1.8x |
| Mon, 12 Jan 2026 | HK$2.7t | HK$1.4t | HK$33.7b | 18.1x | 80.1x | 1.9x |
| Wed, 10 Dec 2025 | HK$2.5t | HK$1.4t | HK$34.6b | 18.3x | 72.9x | 1.8x |
| Fri, 07 Nov 2025 | HK$2.6t | HK$1.4t | HK$35.1b | 18.4x | 73.3x | 1.8x |
| Sun, 05 Oct 2025 | HK$2.8t | HK$1.4t | HK$35.0b | 19.4x | 80.5x | 2x |
| Tue, 02 Sep 2025 | HK$2.8t | HK$1.5t | HK$37.2b | 19.2x | 74.2x | 1.9x |
| Thu, 31 Jul 2025 | HK$2.5t | HK$1.5t | HK$35.5b | 17.3x | 71.6x | 1.7x |
| Sat, 28 Jun 2025 | HK$2.0t | HK$1.5t | HK$33.2b | 14.6x | 60.2x | 1.4x |
| Mon, 26 May 2025 | HK$1.8t | HK$1.4t | HK$33.8b | 14.7x | 52.8x | 1.2x |
| Wed, 23 Apr 2025 | HK$1.6t | HK$1.4t | HK$32.2b | 14.4x | 51.1x | 1.2x |
| Fri, 21 Mar 2025 | HK$1.6t | HK$1.4t | HK$29.4b | 12.4x | 55x | 1.1x |
| Sun, 16 Feb 2025 | HK$1.4t | HK$1.4t | HK$29.1b | 11.8x | 48x | 1x |
| Tue, 14 Jan 2025 | HK$1.2t | HK$1.4t | HK$29.1b | 11.2x | 42.6x | 0.9x |
| Thu, 12 Dec 2024 | HK$1.4t | HK$1.4t | HK$29.2b | 12.1x | 47.7x | 1x |
| Sat, 09 Nov 2024 | HK$1.4t | HK$1.4t | HK$29.2b | 12.6x | 47.3x | 1x |
| Mon, 07 Oct 2024 | HK$1.6t | HK$1.5t | HK$30.9b | 13.8x | 51.4x | 1.1x |
| Wed, 04 Sep 2024 | HK$1.2t | HK$1.5t | HK$29.4b | 11.4x | 42.5x | 0.9x |
| Fri, 02 Aug 2024 | HK$1.2t | HK$1.4t | HK$27.5b | 10.6x | 43.8x | 0.8x |
| Sun, 30 Jun 2024 | HK$1.2t | HK$1.4t | HK$28.7b | 10.8x | 43.5x | 0.9x |
| Tue, 28 May 2024 | HK$1.3t | HK$1.4t | HK$28.5b | 12x | 46.7x | 0.9x |
| Thu, 25 Apr 2024 | HK$1.3t | HK$1.4t | HK$28.3b | 11.5x | 46.1x | 0.9x |
| Sat, 23 Mar 2024 | HK$1.3t | HK$1.4t | HK$27.6b | 11.6x | 47.9x | 0.9x |
| Mon, 19 Feb 2024 | HK$1.3t | HK$1.4t | HK$25.8b | 11.5x | 50.7x | 0.9x |
| Wed, 17 Jan 2024 | HK$1.5t | HK$1.4t | HK$25.9b | 12x | 56.7x | 1x |
| Fri, 15 Dec 2023 | HK$1.5t | HK$1.4t | HK$26.4b | 12.8x | 58.1x | 1.1x |
| Sun, 12 Nov 2023 | HK$1.6t | HK$1.4t | HK$25.1b | 13.1x | 65.7x | 1.2x |
| Tue, 10 Oct 2023 | HK$1.6t | HK$1.4t | HK$24.7b | 12.3x | 63.3x | 1.1x |
| Thu, 07 Sep 2023 | HK$1.6t | HK$1.4t | HK$25.2b | 12.7x | 62.2x | 1.1x |
| Sat, 05 Aug 2023 | HK$1.7t | HK$1.3t | HK$14.1b | 14.8x | 118.7x | 1.2x |
| Mon, 03 Jul 2023 | HK$1.7t | HK$1.4t | HK$2.4b | 13.9x | 692.3x | 1.2x |
| Wed, 31 May 2023 | HK$1.7t | HK$1.3t | HK$3.2b | 13.9x | 535x | 1.3x |
| Fri, 28 Apr 2023 | HK$1.9t | HK$1.4t | HK$4.7b | 15.4x | 405.9x | 1.4x |
| Sun, 26 Mar 2023 | HK$1.9t | HK$1.4t | HK$2.2b | 15.5x | 858.6x | 1.4x |
| Tue, 21 Feb 2023 | HK$2.0t | HK$1.3t | HK$2.1b | 15.7x | 967.3x | 1.5x |
Price to Earnings Ratio
967.3x
Current Industry PE
- Investors are pessimistic on the Hong Kong Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 78.1x which is lower than its 3-year average PE of 113x.
- The 3-year average PS ratio of 1.2x is lower than the industry's current PS ratio of 1.8x.
Past Earnings Growth
- The earnings for companies in the Healthcare industry have grown 154% per year over the last three years.
- Revenues for these companies have grown 2.3% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare sector?
| HK Market | 0.51% | |
| Healthcare | 3.53% | |
| Healthtech | 5.98% | |
| Biotech | 5.62% | |
| Life Sciences | 5.36% | |
| Medical Equipment | 4.11% | |
| Healthcare Services | 1.53% | |
| Pharma | 0.41% | |
Industry PE
- Investors are most optimistic about the Medical Equipment industry which is trading above its 3-year average PE ratio.
- Analysts are expecting annual earnings growth of 48.7%, which is higher than its past year's earnings growth of 17.1% per year.
Forecasted Growth
- Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 73% over the next 5 years.
- This is better than its past earnings decline of 2.2% per year.
- In contrast, the Pharma industry is expected to see its earnings grow by 16% per year over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2659 Shanghai Bao Pharmaceuticals | HK$166.50 | 50.0% +HK$18.1b | n/a | PS1028x | |
| 1801 Innovent Biologics | HK$88.60 | 11.4% +HK$15.8b | 136.3% | PE120x | |
| 2269 WuXi Biologics (Cayman) | HK$40.00 | 6.2% +HK$9.6b | 71.7% | PE34.9x | |
| 3696 InSilico Medicine Cayman TopCo | HK$73.50 | 18.3% +HK$6.5b | n/a | PS100x | |
| 1093 CSPC Pharmaceutical Group | HK$10.11 | 4.7% +HK$5.1b | 110.6% | PE25.2x |